The U.S. Defense Dept. awarded $195.8 million worth of contracts to 3 medical device firms.
And Terumo BCT earned a contract worth up to $29.9 million for its Mirasol system. The Terumo Corp. (TYO:4543) subsidiary is working with the U.S. Army Medical Research & Material Command to develop an FDA-approved whole blood pathogen reduction device. The DoD wants to advance the system for the treatment of donated whole blood used in emergency transfusions in deployed military forces.